Breaking News

Boehringer Licenses ProBioGen’s GlymaxX Technology

Will offer tailored solutions for highly potent antibodies

Author Image

By: Tim Wright

Editor-in-Chief, Contract Pharma

Boehringer Ingelheim and ProBioGen AG have signed a non-exclusive Licensing Agreement under which Boehringer’s Contract Manufacturing Business will apply ProBioGen’s GlymaxX technology to enhance ADCC (Antibody-Dependent Cell-Mediated Cytotoxicity) activity of antibodies. According to the company, the technology can be integrated into Boehringer’s high expression CHO-based BI-HEX system. Both companies will jointly market the technology and offer it to customers royalty free. 
 “We are ve...

Continue reading this story and get 24/7 access to Contract Pharma for FREE


Already a subscriber? Sign in

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters